Find out if IXINITY® is right
for your patients
Watch as real patients share
their IXINITY® IXperience™
Find out if IXINITY is right for your patients
Watch as real patients share their IXINITY® IXperience™
Switch to IXINITY for peak factor IX control
Flexible dosing and effective bleed control support patients’ active, everyday lives. In a clinical trial, 84% of bleeding episodes were resolved with 1-2 infusions.1* For your patients who want predictable bleed control and the benefits of flexible dosing, but are uncontrolled or not satisfied with their current factor IX replacement, consider a switch to IXINITY.
In a clinical trial, 71% of bleeding episodes were resolved with 1 infusion and 13% were resolved with 2 infusions.1
The pharmacokinetics of lXINITY have been evaluated in 32 previously treated patients ≥12 years of age with severe to moderately severe hemophilia B.
The efficacy (n=68) and safety (n=77) of IXINITY have been evaluated in a prospective, open-label, uncontrolled, multicenter trial in which previously treated patients between 7 and 64 years of age received IXINITY in either a routine or on-demand regimen, including 55 patients with more than 50 exposure days and 45 of those patients with more than 100 exposure days.1
Explore more about IXINITY
Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Seattle, WA: Aptevo BioTherapeutics LLC; December 2018.